Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations Cover

.blurhash-client-img { display: none !important; }

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations

Radiology and Oncology

Volume 48 (2014): Issue 4 (December 2014)

By: Matjaz Zwitter, Karmen Stanic, Mirjana Rajer, Izidor Kern, Martina Vrankar, Natalija Edelbaher and Viljem Kovac

Open Access

|Nov 2014

Download Article

Download the full article as a PDF file.

DOI: https://doi.org/10.2478/raon-2014-0038 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 361 - 368

Submitted on: Aug 25, 2014

|

Accepted on: Sep 8, 2014

|

Published on: Nov 5, 2014

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

Non-small cell lung cancer,

EGFR activating mutations,

intercalated therapy,

metabolic response

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2014 Matjaz Zwitter, Karmen Stanic, Mirjana Rajer, Izidor Kern, Martina Vrankar, Natalija Edelbaher, Viljem Kovac, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous article Volume 48 (2014): Issue 4 (December 2014)Next article